LLY Jun 2025 730.000 call
| Previous close | 142.00 |
| Open | 115.55 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 730.00 |
| Expiry date | 2025-06-20 |
| Day's range | 114.80 - 142.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
Insider MonkeyIs Eli Lilly and Company the Largest Publicly Traded Healthcare Company?
In this article, we will be taking a look at is Eli Lilly and Company the largest publicly traded healthcare company? If you wish to learn about more companies, head straight to the Top 20 Largest Publicly Traded Healthcare Companies. Major Players Driving the U.S. Healthcare Industry’s Growth and Innovation The global healthcare industry is […]
Barrons.comHims & Hers Is Selling Copycat Weight-Loss Drugs. Here’s How.
A plan by Hims & Hers Health to sell legal copies of Novo Nordisk weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials. Enormous demand has created shortages of Novo’s Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.
BenzingaAustralia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Australia announced on Wednesday that it would ban compounded versions of weight-loss drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Eli Lilly And Co’s (NYSE:LLY) Mounjaro, citing safety concerns. Recently, the Chinese regulatory authority approved Eli Lilly’s diabetes drug, tirzepatide. Health Minister Mark Butler emphasized that these unregulated copies have not undergone rigorous testing, leading to potential patient risks. Related: The Ozempic Diet: Nestle Launches $5 Pizza For Weight
